Platelet bound complement split product (PC4d) is a marker of platelet activation and arterial vascular events in Systemic Lupus Erythematosus

被引:10
作者
Gartshteyn, Yevgeniya [1 ]
Mor, Adam [1 ]
Shimbo, Daichi [2 ]
Khalili, Leila [1 ]
Kapoor, Teja [1 ]
Geraldino-Pardilla, Laura [1 ]
Alexander, Roberta V. [3 ]
Conklin, John [3 ]
Dervieux, Thierry [4 ]
Askanase, Anca D. [1 ]
机构
[1] Columbia Univ, Med Ctr, Dept Med, Div Rheumatol, New York, NY USA
[2] Columbia Univ, Med Ctr, Ctr Behav Cardiovasc Hlth, Dept Med,Div Cardiol, New York, NY USA
[3] Exagen Diagnostics Inc, Vista, CA USA
[4] Prometheus Biosci, San Diego, CA USA
基金
美国国家卫生研究院;
关键词
Systemic lupus erythematosus; Cardiovascular disease; Thrombosis; Antiphospholipid syndrome; Complement split products; Platelet; Inflammation; Autoimmune disease; Biomarker; DISEASE-ACTIVITY; C4D; CLASSIFICATION; THROMBOSIS; CRITERIA; SIZE;
D O I
10.1016/j.clim.2021.108755
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Platelet-bound complement activation products (PC4d) are associated with thrombosis in Systemic Lupus Erythematosus (SLE). This study investigated the effect of PC4d on platelet function, as a mechanistic link to arterial thrombosis. In a cohort of 150 SLE patients, 13 events had occurred within five years of enrollment. Patients with arterial events had higher PC4d levels (13.6 [4.4-24.0] vs. 4.0 [2.5-8.3] net MFI), with PC4d 10 being the optimal cutoff for event detection. The association of arterial events with PC4d remained significant after adjusting for antiphospholipid status, smoking, and prednisone use (p = 0.045). PC4d levels correlated with lower platelet counts (r = -0.26, p = 0.002), larger platelet volumes (r = 0.22, p = 0.009) and increased platelet aggregation: the adenosine diphosphate (ADP) concentration to achieve 50% maximal aggregation (EC50) was lower in patients with PC4d 10 compared with PC4d < 10 (1.6 vs. 3.7, p = 0.038, respectively). These results suggest that PC4d may be a mechanistic marker for vascular disease in SLE.
引用
收藏
页数:7
相关论文
共 35 条
[1]   Persistent enhanced platelet activation in patients with acute myocardial infarction and coronary microvascular obstruction: clinical implications [J].
Aurigemma, Cristina ;
Scalone, Giancarla ;
Tomai, Fabrizio ;
Altamura, Luca ;
De Persio, Giovanni ;
Stazi, Alessandra ;
Lanza, Gaetano A. ;
Crea, Filippo .
THROMBOSIS AND HAEMOSTASIS, 2014, 111 (01) :122-130
[2]   FcγRIIa Ligation Induces Platelet Hypersensitivity to Thrombotic Stimuli [J].
Berlacher, Mark D. ;
Vieth, Joshua A. ;
Heflin, Brittany C. ;
Gay, Steven R. ;
Antczak, Adam J. ;
Tasma, Brian E. ;
Boardman, Holly J. ;
Singh, Navinderjit ;
Montel, Angela H. ;
Kahaleh, M. Bashar ;
Worth, Randall G. .
AMERICAN JOURNAL OF PATHOLOGY, 2013, 182 (01) :244-254
[3]   Platelet CD154 Potentiates Interferon-α Secretion by Plasmacytoid Dendritic Cells in Systemic Lupus Erythematosus [J].
Duffau, Pierre ;
Seneschal, Julien ;
Nicco, Carole ;
Richez, Christophe ;
Lazaro, Estibaliz ;
Douchet, Isabelle ;
Bordes, Cecile ;
Viallard, Jean-Francois ;
Goulvestre, Claire ;
Pellegrin, Jean-Luc ;
Weil, Bernard ;
Moreau, Jean-Francois ;
Batteux, Frederic ;
Blanco, Patrick .
SCIENCE TRANSLATIONAL MEDICINE, 2010, 2 (47)
[4]   The Human Platelet as an Innate Immune Cell: Interactions Between Activated Platelets and the Complement System [J].
Eriksson, Oskar ;
Mohlin, Camilla ;
Nilsson, Bo ;
Ekdahl, Kristina N. .
FRONTIERS IN IMMUNOLOGY, 2019, 10
[5]  
Gladman DD, 2002, J RHEUMATOL, V29, P288
[6]   Platelet-Mediated Thrombosis From Bench to Bedside [J].
Gurbel, Paul A. ;
Jeong, Young-Hoon ;
Navarese, Eliano P. ;
Tantry, Udaya S. .
CIRCULATION RESEARCH, 2016, 118 (09) :1380-1391
[7]   Anti-citrullinated protein antibodies contribute to platelet activation in rheumatoid arthritis [J].
Habets, Kim L. L. ;
Trouw, Leendert A. ;
Levarht, E. W. Nivine ;
Korporaal, Suzanne J. A. ;
Habets, Petra A. M. ;
de Groot, Philip ;
Huizinga, Tom W. J. ;
Toes, Rene E. M. .
ARTHRITIS RESEARCH & THERAPY, 2015, 17
[8]   Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [J].
Hochberg, MC .
ARTHRITIS AND RHEUMATISM, 1997, 40 (09) :1725-1725
[9]   Cell-bound complement activation products (CB-CAPs) have high sensitivity and specificity in pediatric-onset systemic lupus erythematosus and correlate with disease activity [J].
Hui-Yuen, J. S. ;
Gartshteyn, Y. ;
Ma, M. ;
O'Malley, T. ;
Conklin, J. ;
Eichenfield, A. H. ;
Imundo, L. F. ;
Dervieux, T. ;
Askanase, A. D. .
LUPUS, 2018, 27 (14) :2262-2268
[10]   Platelet pathophysiology, pharmacology, and function in coronary artery disease [J].
Ibrahim, Homam ;
Kleiman, Neal S. .
CORONARY ARTERY DISEASE, 2017, 28 (07) :614-623